Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;10(5):e01013.
doi: 10.1002/prp2.1013.

Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells

Affiliations

Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells

Bashaier Al-Zaid et al. Pharmacol Res Perspect. 2022 Oct.

Abstract

The incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are important regulators of many aspects of metabolism including insulin secretion. Their receptors (GIPR and GLP-1R) are closely related members of the secretin class of G-protein-coupled receptors. As both receptors are expressed on pancreatic β-cells there is at least the hypothetical possibility that they may form heteromers. In the present study, we investigated GIPR/GLP-1R heteromerization and the impact of GIPR on GLP-1R-mediated signaling and vice versa in HEK-293 cells. Real-time fluorescence resonance energy transfer (FRET) and bioluminescence resonance energy transfer (BRET) saturation experiments confirm that GLP-1R and GIPR form heteromers. Stimulation with 1 μM GLP-1 caused an increase in both FRET and BRET ratio, whereas stimulation with 1 μM GIP caused a decrease. The only other ligand tested to cause a significant change in BRET signal was the GLP-1 metabolite, GLP-1 (9-36). GIPR expression had no significant effect on mini-Gs recruitment to GLP-1R but significantly inhibited GLP-1 stimulated mini-Gq and arrestin recruitment. In contrast, the presence of GLP-1R improved GIP stimulated mini-Gs and mini-Gq recruitment to GIPR. These data support the hypothesis that GIPR and GLP-1R form heteromers with differential consequences on cell signaling.

Keywords: BRET4; FRET3; G-protein-coupled receptor1; GIP6; GLP-15; heteromerization2.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
GLP‐1R and GIPR heteromerization. (A) BRET saturation experiments between GLP‐1R‐Nluc and GIPR‐SYFP2 in the absence of ligand (black) or presence of 1 μM GLP‐1 (red) or 1 μM GIP (blue). Data are pooled results from at least three independent experiments performed in triplicate. (B). Agonist‐induced changes in FRET between GLP‐1R‐mTurquoise and GIPR‐SYFP2. Perfusion with 1 μM GLP‐1 (black) resulted in an increase in the FRET signal, whereas treatment with 1 μM GIP (red) decreased the FRET signal. Similar results were obtained in cells transfected with GLP‐1R‐SYFP2 and GIPR‐mTurquoise. Traces are the mean ± SEM displayed as error bars of at least three independent experiments.
FIGURE 2
FIGURE 2
Agonist induced changes in BRET between GLP‐1R and GIPR. (A) HEK‐293 cells expressing a fixed ratio of GIPR‐SYFP2 and GLP‐1R‐Nluc were stimulated with 1 μM of one of the panel ligands shown. Stimulation GLP‐1 or GLP‐1 (9–36) resulted in a significant (p < .001) increase in BRET ratio, whereas stimulation with GIP resulted in a significant (p < .05) decrease in BRET ratio. The mean ± SEM is shown from at least three independent experiments. (B) Peptide ligands used in this study. X = aminoisobutyric acid. GLP‐1, Ex‐4(9 = 39), and GLP‐1 (9–36) are C‐terminally amidated.
FIGURE 3
FIGURE 3
Venus‐mGs recruitment to GLP‐1R and GIPR. Venus‐mGs recruitment to Nluc‐labeled receptor assessed by BRET. (A) Venus‐mGs recruitment to either GLP‐1R‐Nluc or GIPR‐Nluc, stimulated by either GLP‐1 or GIP. (B) Maximum Venus‐mGs recruitment to GLP‐1R‐Nluc or GIPR‐Nluc. (C) Venus‐mGs recruitment to GLP‐1R‐Nluc in the presence of unlabeled GLP‐1R or GIPR stimulated by either GLP‐1 or GIP (D). Maximum Venus‐mGs recruitment to GLP‐1R‐Nluc in the presence or absence of unlabeled GLP‐1R or GIPR. (E) Venus‐mGs recruitment to GIPR‐Nluc in the presence of unlabeled GLP‐1R or GIPR stimulated by either GLP‐1 or GIP (F). Maximum Venus‐mGs recruitment to GIPR‐Nluc in the presence or absence of unlabeled GLP‐1R or GIPR. BRET ratios were expressed as fold‐change over non‐stimulated. The mean ± SEM displayed as error bars, from at least three independent experiments.
FIGURE 4
FIGURE 4
Venus‐mGq recruitment to GLP‐1R and GIPR. Venus‐mGq recruitment to Nluc‐labeled receptor assessed by BRET. (A) Venus‐mGq recruitment to either GLP‐1R‐Nluc or GIPR‐Nluc stimulated by either GLP‐1 or GIP. (B) Maximum Venus‐mGq recruitment to GLP‐1R‐Nluc or GIPR‐Nluc. (C) Venus‐mGq recruitment to GLP‐1R‐Nluc in the presence of unlabeled GLP‐1R or GIPR stimulated by either GLP‐1 or GIP (D). Maximum Venus‐mGq recruitment to GLP‐1R‐Nluc in the presence or absence of unlabeled GLP‐1R or GIPR. (E) Venus‐mGq recruitment to GIPR‐Nluc in the presence of unlabeled GLP‐1R or GIPR stimulated by either GLP‐1 or GIP (F). Maximum Venus‐mGq recruitment to GIPR‐Nluc in the presence or absence of unlabeled GLP‐1R or GIPR. BRET ratios were expressed as fold‐change over non‐stimulated. The mean ± SEM displayed as error bars, from at least three independent experiments.
FIGURE 5
FIGURE 5
Visualization of the cellular location of SYFP2‐ and mTurquoise‐labeled receptors transiently expressed in HEK‐293 cells by confocal microscopy. (A) Representative live cell images of HEK‐293 cells transiently co‐transfected with plasma membrane‐targeted mCherry‐CAAX (red) and SYFP2‐labeled receptor (green) and mTurquoise‐labeled receptor (turquoise). GLP‐1R‐SYFP2 appears to be expressed primarily at the plasma membrane, whereas GIPR‐SYFP2 appears to be located not only at the plasma membrane but also in intracellular compartments. Co‐expression of GIPR‐mTurquoise had no effect on cell surface expression of GLP‐1R‐SYFP2 and GLP‐1R‐mTurquoise did not improve the expression of GIPR‐SYFP2 and the plasma membrane. The images are representative of at least three independent experiments. Scale bar = 5 μm. (B). Colocalization of the SYFP2‐labeled receptors with plasma membrane‐targeted mCherry. GLP‐1R‐SYFP2 colocalizes with membrane‐targeted mCherry to a significantly (****p < .001) greater extent than GIPR‐SYFP2. Co‐expression of GIPR‐mTurquoise had no significant effect on the colocalization of GLP‐1R‐SYFP2 with mCherry‐CAAX. The presence of GLP‐1R‐mTurquoise did not improve the colocalization of GIPR‐SYFP2 with mCherry‐CAAX. Data are the mean ± SEM from values measured in n = 19
FIGURE 6
FIGURE 6
Arrestin3 recruitment to GLP‐1R and GIPR. Arrestin3‐YFP recruitment to Nluc‐labeled receptor assessed by BRET. (A) Arrestin3‐YFP recruitment to either GLP‐1R‐Nluc or GIPR‐Nluc stimulated by either GLP‐1 or GIP. (B) Maximum Arrestin3‐YFP recruitment to GLP‐1R‐Nluc or GIPR‐Nluc. (C) Arrestin3‐YFP recruitment to GLP‐1R‐Nluc in the presence of unlabeled GLP‐1R or GIPR stimulated by either GLP‐1 or GIP (D). Maximum Arrestin3‐YFP recruitment to GLP‐1R‐Nluc in the presence or absence of unlabeled GLP‐1R or GIPR. BRET ratios were expressed as fold‐change over non‐stimulated. The mean ± SEM displayed as error bars, from at least three independent experiments.

Similar articles

Cited by

References

    1. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C‐peptide responses. J Clin Endocrinol Metabol. 1986;63(2):492‐498. doi: 10.1210/jcem-63-2-492 - DOI - PubMed
    1. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon‐like peptide 1 [7‐36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type‐2 diabetes mellitus. J Clin Invest. 1993;91(1):301‐307. doi: 10.1172/JCI116186 - DOI - PMC - PubMed
    1. Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011;34(suppl_2):S251‐S257. doi: 10.2337/dc11-s227 - DOI - PMC - PubMed
    1. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP‐1 receptor agonists in the treatment of type 2 diabetes—state‐of‐the‐art. Mol Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102 - DOI - PMC - PubMed
    1. Flint A, Raben A, Astrup A, Holst JJ. Glucagon‐like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515‐520. doi: 10.1172/JCI990 - DOI - PMC - PubMed

Publication types

LinkOut - more resources